Tracing its roots to Guowei Pharmaceutical, founded in 2005 and reorganized as Sichuan Gowell Pharmaceutical in 2011, the company manufactures and exports vitamin D analogs (calcitriol, paricalcitol, eldecalcitol), the rare disease therapy nusinersen, dutasteride, lubiprostone, dotinurad, morinidazole, and omega-3 products including structured triglycerides and refined olive oil — having been first in China to achieve 90% omega-3 ethyl ester purity. The company invests nearly 30% of revenue in R&D, averaging three approved drug launches (starting with nalmefene hydrochloride injection "Lemeng" in 2008 and moxifloxacin hydrochloride API and injection in 2014), operates a provincial enterprise technology center, and offers CRO services across North America, Europe, Asia, the Middle East, Africa, and Australasia.
No comments available.
Leave your rating & comment